Trial Profile
Randomized, Open Label, Multicenter Phase IIIb Study Evaluating the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant (Response 2)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary) ; Aspirin
- Indications Polycythaemia vera
- Focus Registrational; Therapeutic Use
- Acronyms RESPONSE-2
- Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals
- 12 Dec 2023 Results of pooled analysis of RESPONSE and RESPONSE 2 describing patient benefit of ruxolitinib in patients with PV with or without splenomegaly,presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2022 Results of a study assessing changes of JAK2V617F variant allele fraction in PV and ET patients who were long-term treated with ruxolitinib from tow clinical studies: REPSONSE-1 and RESPONSE-2 presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.